

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue: Suraksha Diagnostic Limited

1. Type of Issue (IPO/FPO) IPO
2. Issue Size (Rs. Cr) INR 846.25 Cr
3. Grade of issue along with name of the rating agency
- Name NA
- Grade NA
4. Subscription Level (Number of times) 1.2635 times (excluding Anchor Portion) as per the bid book of BSE and NSE (excluding the multiple, duplicate bids, Cancelled bids or withdrawal bids, RC 10 and Other than RC 10.)

Source: Minutes of the Meeting held for the finalization of the Basis of Allotment dated December 4, 2024

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue	32.32 %
(ii) at the end of the 1st Quarter immediately after the listing of the issue [^]	NA
(iii) at the end of 1st FY (March 31, 2025) [^]	NA
(iv) at the end of 2nd FY (March 31, 2026) [^]	NA
(v) at the end of 3rd FY (March 31, 2027) [^]	NA

(*) As per the shareholding pattern as on the date of listing.

([^]) QIB Holding not disclosed as reporting for relevant period / fiscal years has not been completed.

6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated

(Rs in Crores)

Parameters	1st FY (March 31, 2025)*	2nd FY (March 31, 2026)*	3rd FY (March 31, 2027)*
Income from operations	N.A.	N.A.	N.A.
Net Profit for the period	N.A.	N.A.	N.A.
Paid-up equity share capital	N.A.	N.A.	N.A.
Reserves excluding revaluation reserves	N.A.	N.A.	N.A.

* Financials not disclosed as reporting for the relevant fiscal years has not been completed.

7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on the BSE Limited and the National Stock Exchange of India Limited .

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)*	N.A.
(ii) at the end of 2nd FY (March 31, 2026)*	N.A.
(iii) at the end of 3rd FY (March 31, 2027)*	N.A.

* Trading status not disclosed as reporting for the relevant fiscal years has not been completed

8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed/ Resigned
(i) at the end of 1st FY (March 31, 2025)*	N.A.	N.A.
(ii) at the end of 2nd FY (March 31, 2026)*	N.A.	N.A.
(iii) at the end of 3rd FY (March 31, 2027)*	N.A.	N.A.

*Changes in directors not disclosed as reporting for relevant fiscal years has not been completed

9. Status of implementation of project/ commencement of commercial production

- (i) **As disclosed in the offer document:** Not Applicable
- (ii) **Actual implementation:** Not Applicable
- (iii) **Reasons for delay in implementation, if any:** Not Applicable

10. Status of utilization of issue proceeds

(i) As disclosed in the offer document:

The objects of the Offer are to (i) carry out the Offer for Sale of up to 19,189,330 Equity Shares of face value ₹ 2 each aggregating to ₹ 8,462.49 million by the Selling Shareholders; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges

(ii) **Actual utilization:** Will be updated in due course

(iii) **Reasons for deviation, if any:** Will be updated in due course.

11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	Not Applicable, as the Offer is an offer for sale of Equity Shares, the Company is not required to appoint a monitoring agency for the Offer.

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12. Pricing Data

Issue Price (Rs.): 441 /-

Designated Stock Exchange: BSE Limited

Listing Date: December 6, 2024

Price parameters	At close of listing day (i.e. December 6, 2024)	At close of 30th calendar day from listing day*	At close of 90th calendar day from listing day*	As at the end of 1st FY after the listing of the issue (May 31, 2025)*		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	417.95	NA	NA	NA	NA	NA
BSE Sensex	81,709.12	NA	NA	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2026)*			As at the end of 3rd FY after the listing of the issue (March 31, 2027)*		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	NA	NA	NA	NA	NA	NA
BSE Sensex	NA	NA	NA	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: BSE website

* Pricing Data not disclosed as reporting for the relevant fiscal years has not been completed

13. **Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)**

Accounting Ratio		As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2025) ⁽²⁾	At the end of 2nd FY (March 31, 2026) ⁽²⁾	At the end of 3rd FY (March 31, 2027) ⁽²⁾
EPS	Issuer:	--	--	--	--
	Consolidated (Basic)	4.43	N.A	N.A	N.A
	Consolidated (Diluted)	4.43	N.A	N.A	N.A
	Peer Group :	--	--	--	--
	Dr Lal Path Labs	Basic – 43.05 Diluted – 42.98	N.A	N.A	N.A
	Metropolis Healthcare	Basic – 24.95 Diluted – 24.87	N.A	N.A	N.A
	Thyrocare	Basic – 13.42 Diluted – 13.40	N.A	N.A	N.A
	Vijaya Diagnostic	Basic – 11.62 Diluted – 11.59	N.A	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A
P/E	Issuer:	--	--	--	--

	Consolidated		N.A	N.A	N.A
	Peer Group	--	--	--	--
	Dr Lal Path Labs	77.08	N.A	N.A	N.A
	Metropolis Healthcare	89.61	N.A	N.A	N.A
	Thyrocare	65.52	N.A	N.A	N.A
	Vijaya Diagnostic	86.40	N.A	N.A	N.A
	Industry Composite:	79.65	N.A	N.A	N.A
RoNW (%)	Issuer:	--	--	--	--
	Consolidated	14.09	N.A	N.A	N.A
	Peer Group	--	--	--	--
	Dr Lal Path Labs	20.35	N.A	N.A	N.A
	Metropolis Healthcare	12.26	N.A	N.A	N.A
	Thyrocare	13.34	N.A	N.A	N.A
	Vijaya Diagnostic	19.77	N.A	N.A	N.A
	Industry Composite:	NA	N.A	N.A	N.A
NAV	Issuer:	--	--	--	--
	Consolidated	33.66	N.A	N.A	N.A

	Peer Group	--	--	--	--
	Dr Lal Path Labs	221.53	N.A	N.A	N.A
	Metropolis Healthcare	213.98	N.A	N.A	N.A
	Thyrocare	99.48	N.A	N.A	N.A
	Vijaya Diagnostic	64.21	N.A	N.A	N.A
	Industry Avg:	N.A	N.A	N.A	N.A

Notes:

- (1) Prospectus dated December 3,2024.
(2) Not disclosed as the reporting for the relevant fiscal years has not been completed.

14. Any other material information

Particulars	Date
Nil	

Source- Stock Exchange Filings

All the above information has been updated till December 6,2024, unless indicated otherwise.